Literature DB >> 26634607

Three unsuccessful treatments of Helicobacter pylori infection by a highly virulent strain with quadruple antibiotic resistance.

Lyudmila Boyanova1, Ivailo Evstatiev2, Daniel Yordanov3, Rumyana Markovska3, Ivan Mitov3.   

Abstract

We report a case of an adult patient undergoing three unsuccessful Helicobacter pylori treatments, including proton pump inhibitor (PPI), bismuth subcitrate, metronidazole and tetracycline in 2012, PPI, amoxicillin and clarithromycin in 2013, and PPI, amoxicillin and rifampin in 2014. Following the first treatment, the isolate was metronidazole and ciprofloxacin/levofloxacin resistant. After the second treatment, the isolate was resistant to metronidazole, ciprofloxacin/levofloxacin and rifampin, developing secondary clarithromycin resistance by A2143G mutation and was susceptible only to tetracycline. After the third treatment, the patient still remained H. pylori positive. Patient's strain was highly virulent (cagA (+) , cagE (+) and vacA s1a/m1/i1). The evolution of the patient's disease was from gastroesophageal reflux disease in 2012 to two duodenal ulcers in 2015. Briefly, the infecting strain showed quadruple antibiotic resistance and a transient amoxicillin resistance. Triple clarithromycin-based treatment induced secondary clarithromycin resistance by A2143G mutation, while rifampin resistance caused the third treatment failure. Several options for the next treatment regimens are discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26634607     DOI: 10.1007/s12223-015-0439-2

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  12 in total

1.  Fosfomycin-containing second-line treatment for Helicobacter pylori infection.

Authors:  Josué Barahona-Garrido; Nery F Quiñonez; Eduardo Cerda-Contreras; Helga Maria Sarti; Félix I Téllez-Ávila
Journal:  Am J Gastroenterol       Date:  2013-05       Impact factor: 10.864

Review 2.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.

Authors:  Vasilios Papastergiou; Sotirios D Georgopoulos; Stylianos Karatapanis
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 3.  Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

Authors:  J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

4.  Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico.

Authors:  J Torres; M Camorlinga-Ponce; G Pérez-Pérez; A Madrazo-De la Garza; M Dehesa; G González-Valencia; O Muñoz
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.

Authors:  Ruggiero Francavilla; Elena Lionetti; Stefania Castellaneta; Marcella Margiotta; Domenico Piscitelli; Lorenzo Lorenzo; Luciano Cavallo; Enzo Ierardi
Journal:  J Pediatr       Date:  2010-04-18       Impact factor: 4.406

6.  High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients.

Authors:  Lyudmila Boyanova; Rumiana Markovska; Daniel Yordanov; Maya Marina; Katusha Ivanova; Stephan Panayotov; Galina Gergova; Ivan Mitov
Journal:  Diagn Microbiol Infect Dis       Date:  2009-08       Impact factor: 2.803

7.  Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin.

Authors:  Takahisa Furuta; Yoshihiro Soya; Mitsushige Sugimoto; Naohito Shirai; Akiko Nakamura; Chise Kodaira; Masafumi Nishino; Masumi Okuda; Tadayoshi Okimoto; Kazunari Murakami; Toshio Fujioka; Akira Hishida
Journal:  J Gastroenterol Hepatol       Date:  2007-11       Impact factor: 4.029

8.  Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods.

Authors:  Lyudmila Boyanova; Galina Gergova; Rossen Nikolov; Lubomir Davidkov; Victor Kamburov; Christo Jelev; Ivan Mitov
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-14       Impact factor: 2.803

9.  Significance of Helicobacter pylori vacA intermediate region genotyping-a Bulgarian study.

Authors:  Daniel Yordanov; Lyudmila Boyanova; Rumyana Markovska; Galina Gergova; Ivan Mitov
Journal:  Diagn Microbiol Infect Dis       Date:  2012-08-28       Impact factor: 2.803

Review 10.  Treatment of Helicobacter pylori infection: current status and future concepts.

Authors:  Jyh-Chin Yang; Chien-Wei Lu; Chun-Jung Lin
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

View more
  2 in total

1.  1,4-Dihydropyridine as a Promising Scaffold for Novel Antimicrobials Against Helicobacter pylori.

Authors:  Andrés González; Javier Casado; Miyase Gözde Gündüz; Brisa Santos; Adrián Velázquez-Campoy; Cristina Sarasa-Buisan; María F Fillat; Milagrosa Montes; Elena Piazuelo; Ángel Lanas
Journal:  Front Microbiol       Date:  2022-05-25       Impact factor: 6.064

2.  Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA.

Authors:  Andrés González; Sandra Salillas; Adrián Velázquez-Campoy; Vladimir Espinosa Angarica; María F Fillat; Javier Sancho; Ángel Lanas
Journal:  Sci Rep       Date:  2019-08-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.